Cytek Biosciences (CTKB) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
10x Genomics (TXG) has outperformed Cytek Biosciences (CTKB) over the past year, gaining 540.3% versus a gain of 37.4%. Over five years, TXG leads with a -49.2% price change compared with -77.7% for CTKB. 10x Genomics is the larger company by market cap ($10.07 billion vs $696.7 million), about 14.5 times the size.
On valuation, Cytek Biosciences trades at a lower forward P/E (76.6x vs 1008.0x for 10x Genomics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | TXG |
|---|---|---|
| Share price | $5.36 | $77.28 |
| Market cap | $696.71M | $10.07B |
| 1-day change | +0.37% | +1.55% |
| YTD return | +6.14% | +373.82% |
| 1-year return | +37.44% | +540.27% |
| 5-year return | -77.73% | -49.25% |
| Forward P/E | 76.57 | — |
| EPS (TTM) | $-0.62 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $642.82M |
| Revenue growth (YoY) | — | +5.25% |
| Net income (latest FY) | — | $-43.54M |
| Gross margin | — | 69.05% |
| Operating margin | — | -9.49% |
| Net margin | — | -6.77% |
| 52-week high | $6.21 | $102.81 |
| 52-week low | $3.31 | $11.16 |
| Distance from 52-week high | -13.69% | -24.83% |
| Analyst consensus | none | buy |
| Avg. price target upside | +3.73% | -12.69% |
| Average volume | 1.04M | 3.25M |
| Shares outstanding | 129.98M | 120.21M |
| Employees | 682 | 1,178 |
| Sector | Industrials | Healthcare |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 10x Genomics is about 14.5 times larger than Cytek Biosciences by market value ($10.07B vs $696.71M).
- TXG has outperformed CTKB by 502.8 percentage points over the past year.
- The two companies sit in different sectors: Cytek Biosciences in Industrials and 10x Genomics in Healthcare.
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Healthcare · Medical Devices · 1,178 employees
CTKB vs TXG FAQ
Which is bigger, Cytek Biosciences or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $10.07B compared with $696.71M for Cytek Biosciences (CTKB).
Which stock has performed better over the past year, CTKB or TXG?
TXG returned +540.27% over the past 12 months, compared with +37.44% for CTKB (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and 10x Genomics in the same industry?
No. Cytek Biosciences is in the Industrials sector, while 10x Genomics is in Healthcare.